Celltrion's Quadruple-Action Obesity Drug Beats Rival on Weight Loss and Muscle Preservation in Preclinical Study; U.S. Trial Set for 2027
Source · BigGo Finance
TLDR
Celltrion reported that CT-G32/SCO-940, co-developed with SCOHIA PHARMA, produced greater weight loss and a lower proportion of lean-mass loss than Retatrutide in animal studies. The four-pathway obesity candidate remains preclinical; Celltrion plans an FDA investigational new drug application in February 2027 and clinical entry in the second quarter, subject to regulatory review.
- 01The candidate targets GLP-1, GIP, glucagon and amylin in a single molecule.
- 02Celltrion presented animal results at TIDES Europe, reporting reduced blood insulin alongside weight and body-composition findings.
- 03Human efficacy, safety and tolerability remain unverified; the excerpt provides no numerical weight-loss results.
Why it matters Editorial
The findings suggest a potential approach to weight loss with less proportional lean-mass loss, but clinical trials are needed to determine whether the animal results translate to humans.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
Caribbean National Weekly
Johannesburg Sunday World